Crohn’s disease, a chronic inflammatory condition, belongs to a group of conditions known as inflammatory bowel diseases (IBD). It most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus. Dr. Kevin Tracey’s research into bioelectronic medicine is currently being used in clinical trials directed at patients with Crohn’s disease, a condition currently afflicting more than 700,000 Americans. SetPoint Medical, a company Dr. Tracey co-founded, is conducting the trials at five European research centers. During the trials, a device will be implanted to stimulate the vagus nerve in order to activate the body’s natural inflammatory reflex and induce the production of natural anti-inflammatory effects.
- SetPoint announces first trial of bioelectronic therapy to treat Crohn’s diseaseSecond study in humans to evaluate bioelectronic medicine for autoimmune disease